CSF3 and neutropenia: For the CUP and EAP studies, the protocols stated that primary prophylaxis with G-CSF (defined as use during Cycle 1; secondary prophylaxis defined as use in any subsequent cycle) should be considered in patients with high-risk clinical features that may predispose them to increased complications from prolonged neutropenia (≥65 years of age, poor performance status, previous episodes of febrile neutropenia, extensive prior radiation ports, poor nutritional status, or other serious comorbidities).